Navigation Links
Drug Eases Gout Flare-ups in Some Patients: Study
Date:1/5/2012

By Alan Mozes
HealthDay Reporter

THURSDAY, Jan. 5 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.

In a new study, the protein-inhibitor drug rilonacept (Arcalyst) appeared to markedly lower the risk of gout flare-ups during the first few months of treatments aimed at lowering uric acid levels.

While effective in lowering the risk for gout attacks in the long-term, uric acid-lowering treatment can initially boost the risk for flare-ups as it breaks up and releases the uric acid crystal deposits at the source.

"To reduce deposits of crystals in the joints, we advise patients to initiate treatment with medications that lower levels of uric acid in the blood," study author Dr. H. Ralph Schumacher, Jr., a professor of medicine at the University of Pennsylvania School of Medicine, said in a journal news release.

Gout, a debilitating and painful form of inflammatory arthritis, now affects upwards of 8.3 million Americans, according to the release. Flare-ups , which involve excruciating joint pain, redness, swelling and warmth, can last days or weeks.

The researchers wanted to learn if rilonacept could lower this short-term risk for by neutralizing a specific target protein -- interleukin 1 or IL-1 -- before it initiates inflammation.

They looked at 83 gout patients in 27 U.S. study centers who had a history of gout flare-ups and high levels of uric acid. All were placed on a chronic uric-acid lowering regimen of the standard drug allopurinol.

About half were also given an initial double-dose injection of rilonacept (320 milligrams) followed by a single dose for 16 weeks. The other half received sugar pills.

Rilonacept patients were less likely to have flare-ups, with 15 percent experiencing flare-ups three-months into the study compared with 45 percent among the non-rilonacept group, the researchers found.

"Well-tolerated drugs that reduce the risk of gout flares when initiating uric-acid lowering therapy could make patients more likely to continue important long-term treatments that control gout," Schumacher said in the release.

"(And) this trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting," he added. "Rilonacept appears safe and well tolerated and could increase patient adherence to long-term urate-lowering therapy."

The study appeared online Jan. 5 in the journal Arthritis & Rheumatism.

Dr. Michael A. Becker, a professor emeritus of medicine at the University of Chicago, described the findings as "very promising." However, he cautioned that the high cost of rilonacept will most likely curtail its use.

"This is a very expensive drug," he said. "And insurance will be an issue. So I think you will have to carefully justify its use and define the universe of patients who are likely to be treated with it."

"But there are a number of patients who can't take a less expensive alternative, such as nonsteroidal anti-inflammatory drugs, because of their kidney function or ulcer disease," Becker noted. "So for this population of patients who can't tolerate cheaper medications, rilonacept may be a necessary indication."

More information

For more on gout, visit the U.S. National Library of Medicine.

-- Alan Mozes

SOURCE: Michael A. Becker, professor emeritus, medicine, University of Chicago; Arthritis & Rheumatism, news release, Jan. 5, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Sexual satisfaction in women increases with age
2. As Gastric Banding Increases, So May Complications
3. Inhaled glucocorticoids during pregnancy and offspring pediatric diseases
4. Researchers investigate link between autoimmune diseases and wounds that dont heal
5. Presidents Bioethics Commission releases report on human subjects protection
6. Insulin signaling is distorted in pancreases of Type 2 diabetics
7. Blue light irradiation promotes growth, increases antioxidants in lettuce seedlings
8. Scientists identify strategies to conquer lifestyle and genetic factors related to chronic diseases
9. Poorly contracting uterus in diabetic women increases risk of caesarean birth
10. Chinese health coverage increases with new government efforts
11. Norwegian study finds opening bars longer increases violence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Eases Gout Flare-ups in Some Patients: Study
(Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and delivered ... order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige Delivery ... only 15 miles away from Flint. , “We have deep roots in the local ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... NASHVILLE, Tenn. (PRWEB) , ... February 10, 2016 ... ... by the American Academy of Emergency Medicine , an emergency medicine ... of practice management services . , The American Academy of Emergency Medicine, ...
(Date:2/10/2016)... ... 2016 , ... Emergency rooms provide emergency care to stabilize critical health issues, ... with dental emergencies at risk of losing a tooth or their smiles. Dr. Marine ... Common dental emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... CO (PRWEB) , ... February 10, 2016 , ... Dr. ... announce the practice is now accepting new dental patients and families in the North ... exceptional dental care services from cleanings to cosmetic dentistry, and all in the most ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 Puerto ... --> Puerto Rico Healthcare and Life Sciences Report 2016 ... 61 page Puerto Rico Healthcare and Life Sciences Report ... insights into the fifth largest territory in the world for ... medical device and diagnostics manufacturing, and more universities per square ...
(Date:2/10/2016)... 10, 2016 CERS ), Medivation, Inc. ... ) and Celldex Therapeutics, Inc. (NASDAQ: CLDX ). ... Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, ... Orphan Drug Designations become vitally important in the development of ... drugs and biologics which are defined as those intended for ...
(Date:2/10/2016)... ALBANY, New York , February 10, 2016 ... Share, Growth, Trends and Forecast 2015 - 2023 ", reveals ... a rather slow growth from 2015 to 2023 owing to ... register a meager CAGR of 1.30% during the forecast period, ... 2014 to US$38.9 bn in 2023. --> Antibacterial ...
Breaking Medicine Technology: